Two-year Effect of Semaglutide 2.4 mg Versus Placebo in Adults With Overweight or Obesity: STEP 5

The 2-year efficacy and safety of once-weekly (OW) subcutaneous semaglutide 2.4 mg versus placebo in adults with overweight/obesity was assessed in STEP 5 (NCT03693430). In STEP 5 (phase 3, double-blind, placebo-controlled trial), adults with body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 with ≥1 weight-related comorbidity, without diabetes, were randomized 1:1 to 104 weeks’ treatment with OW semaglutide 2.4 mg or placebo. Co-primary endpoints were percent change in body weight (BW) and achievement of ≥5% weight loss.